DNA(Ginkgo Bioworks Holdings, Inc.) · 财务报表

DNA(Ginkgo Bioworks Holdings, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$313.84M$477.71M$251.46M$227.04M$170.16M
毛利润—————
营业利润−$1.83B−$2.21B−$864.41M−$559.76M−$315.28M
净利润−$1.83B−$2.10B−$892.87M−$547.03M−$312.76M
经营现金流−$253.82M−$252.20M−$295.50M−$319.58M−$171.06M
自由现金流−$310.34M−$304.47M−$336.30M−$382.13M−$178.72M
摊薄每股收益$-55.60$-50.20$-18.37$-10.54$-5.64

Ginkgo Bioworks Holdings, Inc. DNA